[00:00:01] Host Create clip all right. It is my pleasure to bring on stage an incredible CEO for an incredible company. You may not have heard of Sam u Med, but it is one of most miraculous companies in the vitality and longevity space that I know of. Dr. Oz Monkey Bar has two bachelors degrees, one in engineering from Cal Tech. Ah, he has ah, a M s and a PhD in bio photonics and hopped electronics from UCSD. And what you're about to hear from him is nothing more than extraordinary. Uh, this is a company that you may have heard off, but it's a $13 billion private company decoding how the human cell and hopefully vitality on chubby life is so Please welcome Dr Oz Manky bar.

[00:00:58] Host Create clip Thank you. Good morning. So we have ah drug development platform where we are able to restore the health off any tissue in the body Back to how it was before off course there some regenerative medicine applications. You know, in these cases, if a certain tissue let's say you wore out your cartilage, then we have ah, small molecule drug that would regenerated back thio healthy level, but then they're certain diseases where there's too much replenishment going on. For example, cancer, in which case our drugs haven't enter proliferated effect. And the last one is if our own immune systems are attacking a certain tissue in the body, then we have these anti inflammatory drugs. So the problem we all face is that as we age or health deteriorates and then we die. That's what we call ageing, and we usually take it for granted. And to address this problem. Hey, I wanna give a quick background on stem cell biology in the simplest storms, when the first fetuses formed the Ignatz the sperm, we have our first embryonic stem cells.

[00:02:21] Host Create clip That's the top layer. Think of it as a pyramid. So we're talking about the peak of the pyramid. Embryonic means that stem cell has the capacity to turn into any other type of cell in the body. Then, as the fetus starts growing, that embryonic stem cell multiplies into more embryonic stem cells. 248 16 and so on, and at some point they start coordinating and communicating with each other, and they partially differentiate the keyword this partial and they differentiate into all the different types off progenitor of stem cells. That's the middle layer. Now each progenitor stem cell is in charge of a particulate system in the body. For example, my Giacomo stop stem cells are in charge of the musculoskeletal system, so they further differentiate and turned into a bone. Cartilage, tendons, ligaments, muscles. But they cannot turn into a skin cell or a brain cell or a heart. Sir. Dermal stem cells everything to do with the skin epithelial internal organs, a panda, Mel's nervous system, so on and so forth. So we probably have maybe 12 15 different types of progenitor of stem cells, and when they further differentiate, they form all the adult tissues and organs. At that point, there is no stem cell, miss left. That's the bottom layer, and now we have the body.

[00:03:43] Host Create clip Now this is all happening in the world when the baby's born, all the embryonic stem cells are gone. The president of stem cells, however, they remain embedded in our local tissues until the day we die, and their job is to repair and replenish and basically maintain the health off the specific tissues they are responsible for. For example, we break a bone missing camo stem cells jump into action. Ah, first they multiply. Then they differentiate down toe austere blessed, which are the born building cells, calcium deposition and so on, and they repaired the ball. Now instead, we go out running. We were out or cartilage the same Miss Anka most themselves. This time they must apply about to go down a contra site lineage, which are the cartels. Building cells meant the key developmental pathway that regulates the proliferation and the differentiation off the stem cells is what's called the wind pathway Wnt you can think off. First of all, Ah, biological pathway is just a collection of biomolecules, so genes, proteins, peptides, enzymes and when they work together, they set this fire specific function in the body.

[00:04:59] Host Create clip In this case, stamps out the regulation so you can think of it as, ah multiple diameter modulation scheme where certain combination off genes and proteins can get down, regulated or up regulated in a specific ah combination. And then the Maison camo stem cells know whether they should be making more born more cartilage, how much went to stop, or whether they should just sit back and wait until they're needed. The next time around. Now, quick word on the wind pathway. What's very relevant for drug development is that the wind pathway is extremely well conserved across all animal species. What that means is all the genes and proteins that make up the pathway. They're not just similar but identical across all animal species. So when we are tryingto identify a drug molecule, let's say, and we show that it grows cartilage in rats. It's basically 100% certain to that the same molecule is going to grow cartilage in dogs, monkeys and humans alike. So by the time we put one off our disease programs into the clinic into human testing, we basically have the efficacy box more like more or less checked.

[00:06:26] Host Create clip And as we get older, the various signaling levels off the wind pathway start drifting out of balance. And every time that happens, there's a disease associated with that. So if the healthy went levels get out of the healthy range such that there is not enough born replenishment than we have osteoporosis, not enough cartilage osteoarthritis. Not enough. Here we go bald to me, Nicole and sells. Now we have colon cancer, so every time some imbalance happens. For whatever reason, it could be your lifestyle choices. You know you're a smoker drinker, sports injuries, genetic mutations or just by virtue of aging. The result is to say, and what we do is we develop small molecule drugs that restored the various wint. Activity levels back into a healthy range, at which point the body's own machinery takes over. And they repair and replenish, sometimes up, sometimes down the various tissues that are in distress that have been diseased or damaged. So that's the gist of our platform. Now we have a number off programs that are currently in human testing.

[00:07:54] Host Create clip The one of the most advanced once is we have a molecule that can regenerate cartilage. So these are pictures off on animals and me, the left side, the right lines in the middle of the picture. That's cartilage. And then in the middle picture. In this model, we, ah, it clipped old ligaments. Slmc lpc. Also, there's no structural support. Animals walk around for a couple of months. Born grinds on bone, cartilage wears out, inflammation sets in, and they develop osteoarthritis just like in humans. And then this particulate drunk. It's a single injection injected into the synovial fluid into the knee, and over a matter off months, it grows the cartilage back. That's the picture on the right, even back to healthier level done before. If you compare the thickness off that cartilage with the picture on the left and inflammation is suppressed, the bone spurs are eliminated, and this is while the ligaments are still clipped. So its able to restore the health of the overall joint above and beyond the winter that's going on.

[00:09:08] Host Create clip So we took this molecule into humans. These are human X rays from clinical trials. The picture on the left, the right edge. That's the medial. That's the inside off the knee. Basically, when I human gets osteoarthritis, the most weight bearing point in the body is the medial off the knee. When he loses the cartel, it the top and bottom born plates come closer together. There's a corresponding increase on the lateral side on the outside of the knee, and then again, single injection. We grow cartilage on the inside off the knee, and the two bone plates tilt back to a healthy level, and there's a corresponding decrease on the lateral side. So for this program. We finished the phase one a face to face to be, and we are planning to go into our face. Three pivotal studies Next quarter, Another program. If you take the same injection but now injected into the spine, we are able to regenerate a whole new desk. So again, on the left, that's the disk over healthy. But Ole's Animals disc the one in the middle.

[00:10:21] Host Create clip We basically removed the desk altogether. It's completely destroyed. Single injection, the picture on the right. We're able to regenerate a whole new disc, and it's the same story such that the stem cells don't know how to regenerate all cells. So when they regenerate and restore the health, it actually restores that particulate tissue back to how you had it as a teenager at the peak of your health. So this is also in human trials in It'll program tendon repair on the left. That's a healthy attendant. You have these thin, long filaments. The picture in the middle that's when the attendant structure has been lost in themselves, have penetrated. In this case, the drug is a lotion. You just put it on over the damaged tendon. Once a day and were able to repair the tendon back to how it was before the one on the right. So for this one again, we finished the Phase one another skin sensitization safety study. And with this one, at this point, there is no approved drug for tendon repair, not even a painkiller.

[00:11:33] Host Create clip And we went to the FDA, FDA said, Well, you've got to design your own questionnaire. Your own patient reported outcome such that and then clinically validated, and we'll use that questionnaire to assess you moving forward. So we did that. We just got the green light. So we're going into face, too early next year. Thank you. Another program. We have an oncology pill, this one we designed that there's a pill so it goes everywhere in the body, such that it treats both primary tumors and metastatic tumors because you never know where the tumor has metastasized. This is the same pill applied to eight different indications again in these pictures. These are all primary human tumors implanted into animals. At the top. You can see, you know, colorectal, pancreatic, triple negative, breast, liver and in each case, why access shows the size of the tumor X axis is a matter of three weeks. If untreated, the tumor's keep growing. And when treated with our drug, we basically inhibit growth off the tumors and eliminate them.

[00:12:50] Host Create clip And this one is also in phase one. And anecdotally, we have a couple of patients that have been used in our drug for months now under a compassionate use, and we're glad to say both patients are doing well. You know one of them? It was, Ah, pancreatic cancer patient in her late thirties terminal. All treatments had failed. Six months later, she's traveling. She has gained £40. She's dating, you know, back to normal. So, so far, so good. Another program. This is for Alzheimer's. On the left, you see a slice off a healthy animals brain stem. And then these are transgenic animals, you know, with a specific genetic mutation where they develop Alzheimer's early onset, the one in the middle. All those dark spots are the new a fibula rectangles. And then again, we have a different pill. You take it once a day, and the spill has the property where it is ableto penetrate the blood brain barrier. But at the same time it accumulates Maurine the brain tissue than in the blood. So you take a small dose every day clears from the blood, so there are no side effects.

[00:14:13] Host Create clip But then day after day, it accumulates in the brain and gets to unification stores. So we've also done functional tests. You know, we've looked at cognition, uh, special memory, motor function, even anxiety levels. Everything goes back to normal. And besides these, you know, I'm not showing every program we have, but we have, ah official program where we are able to grow new hair, so that one is currently in phase three. And then we have another lotion where we are able to eliminate wrinkles. That one we partnered with a cosmetic company. Already. We have an inhaler that is able to reverse the scarring in the lungs for pulmonary fibrosis re part mint, that also with another former company. We have a psoriasis program and we have a So these are all in the clinic in human testing, and then we have a number of programs in our pipeline that are coming up. Ah, some of them more exciting than others. So our approach, we basically, you know, I think you can think of it as, ah, spare parts business, right? As we age, we all have different parts off our bodies that age more than you know the rest off us. And we get diseases in this case, you know, just like when you're driving a car, you were out your tires, you put a new tires and the car continues running as good as new.

[00:15:53] Host Create clip In this case, same way you were at your cartilage. We're working on a drug that regenerates cartilage regenerate born regenerate muscle brain tissue, the different parts of the body. So we go at increasing health, spent tissue by tissue, disease by disease. And in each case, the drug is optimized for the particulate disease for the particulate tissue. So obviously, as you eliminate one disease after another, the immediate direct consequences were able to increase the health span and indirectly, that allows us to live longer. In addition, toe living healthier. So that's the life span benefit. So the idea is, you know, we prefer to use the word de aging because anti aging you stop the aging process. We believe we are able to reverse it back to how the body had it when we got healthy. Thank you.

[00:17:01] Host Create clip Amazing, huh? How many folks did not know about Sam? You made before this presentation? Did not know how many folks are super excited about what they're doing. Yeah, So let me let me bring out first off my co host, Dr Bob. Hurry, Bob. Coming out, brother. Let's also bring out Dr David Caro and Dr Amy Wagers. We've got the Doctor's Club. All right, please take a seat. One more's coming out here. Well, uh, so I figure just a little bit of five minutes a conversation here and then please line up. Bob, you wanna throw out the first question, perhaps to the group. So one of the interesting aspects of all the presentations is that there appears to be a soup out there that'll turn your younger right whether it's a combination of factors that are elaborated by stem cells or signalling molecules that we need toe better understand how to modulate systems. There's something out there we have a good handle on that could be administered. Um, Azaz, a discreet therapeutic. I talked about cells, but there's also this discreet therapeutic opportunity, so I wanted to ask Amy your work on the work of your of your team. Ah has focused, been very, very focused on on a very, very select array of factors Where all should we be looking? So our work is focused on blood systemic factors because we think that they're particularly accessible. And I think that that that turns out to be the case and that they have access for potentially cross cutting applications. I think the nervous system in the immune system are also following that same category. They connect different organ systems. They're important for coordinating responses that air physiologic and appropriate. And they're clearly changing with time in in ways that alter the mechanisms that that cells and organs communicate with one another. I think those air to areas that are obviously not mutually exclusive with each other, or even with other circulating factors stem cell derived factors, these sorts of things, but but areas of interest.

[00:19:16] Host Create clip So the immune system obviously is that plays a critical role in everything, and we have access to immune cells from, like you said from blood on there. There's a There's a lot going on now in using in engineering and themselves. You think there's any application of the new new technology and Carty on DDE specifically targeting cells? Absolutely. So this idea to harness the intrinsic protective functions of the immune system to eliminate damage cells, for instance that accumulate with agent could have negative consequences eliminates in essence cells. I think these air applications they they need the identification of specific and selective targets that the immune cells can Can you be attracted to? But I think it's a It's a promising area. Doctor Caro. David, Uh, the numbers you quoted that 40% of people coming in through the health nucleus. These are wealthy individuals, right? They're paying 5000 bucks. Whatever the case may be, um, 40% have a significant finding, and I think 14% need to take action on a finding. Do those numbers sort of shock you? Ah, they do. And they don't, um you know, um, they do in the sent shock me that, uh, you know, the 15% that have a clinically significant actionable finding. We didn't think it was gonna be that high. We thought we'd be finding tumors and aneurysm. But then we added up all the rare monitor Nick Variance the new P R. C A. One mutations. Ah, the new element a cardiomyopathy tze and so forth. But in a way, it doesn't shock me because we know that what has been guiding decisions support for the last 30 years has been this very sort of superficial physical that hasn't been very data driven on it hasn't been very deeper quantitative. So, you know, it's kind of like garbage in garbage out. And the same goes for machine learning algorithms, right? If you're gonna use machine learning algorithms to predict your risk for chronic age related disease, you've really gotta have high quality, continuous quantitative data in. And if you just have a lot of superficial data, the outcome is not very high. So So, in a way, I don't think it's that surprised when you think about what the historical nature of our detection has been.

[00:21:28] Host Create clip So in the audience, I know there is. There are a lot of practicing physicians and other health care providers. Ah, how many of you are using genomic data as part of your work up or part of your decision making tree? When managing your patients just have a show of hands, so it's still still a relatively limited number. What? What? I mean, I actually believe in, you know, I think this again. I'll go back to you, David. I think at the end of the day, we have to be working to create tools and the forms of applications. And I know that at a July we've been quite good at reducing very complicated computational processes into things like search engines and so on. What do you think? The best tools that would be for the general practicing public? Yeah. I mean, I would just make a comment before getting to your, uh, the answer to your question, which is that, you know, 3% of you raised your hand. You know you're using Gina. Typing is part of your practice, but in a way, that cat's out of the bag, right? Because there's a huge consumer genetic component, even a recreational genomic component that's growing rapidly. It's 23 me with five million customers ancestry with 15 million Ah, in a number of others. So you know whether or not you're using in your practice, your your patients are using it. Many of you Ah, in the audience, I imagine, or 23 the customers. So you're using that data. But unfortunately, a lot of that data, just like the 30 year physical exam, is very superficial. And so that 23 me chip looks at 700,000 markers of six billion base pairs. So, for example, the Braca gene B R C. A one gene that's evaluated by 23 me Did you know there's 1000 medically significant variants of the Braca gene and 23 me reports on three Well, so that's a stunning, sobering statistic. So to get to your answer to your question, Bob, it's, you know, we have to come up with sort of lay person friendly algorithms that integrate this deep quantitative data in meaningful ways. I think that's what we tried to do it. H Ally is you know, too, six billion base pairs into still it down to what does that mean for you? What does that mean for your risk in the next one year, five years? And based on that data, what's the number one thing I can do to mitigate my risk and that's gonna be super important And by the way, a lot of that were not revealed to us humans. It's a I machine learning algorithms. Dr. Q. Bar.

[00:23:56] Host Create clip Osmund, Uh, I mean the results. You're showing our extraordinary and I'm gonna ask you some questions, asked David, Did they Are you surprised by how good the early results are in your went pathway? Manipulation?

[00:24:15] Host Create clip Surprised? Not really, because there has been a huge amount off literature, scientific work on the wind pathway. So the translation from anyone animal species into another has been established decades ago. No, What we are specifically, you know trying to do is make sure we never asked the body to do something that the body didn't already know how to do it. So when we are, let's say we're talking about an injection that grows cartilage. We know for a fact that the body has the machine read both the hardware and the software that it has been regenerating that cartilage the right way all our lives. And then there comes a point where that signaling gets out of balance and it can no longer do that. So once we bring that signaling back into a healthy range, we don't have Thio forced the body to do anything from there. It's a chain reaction. The body knows exactly what to do. So the same approach actually applies across all tissues, all organs, but not just at the tissue level. But now we are.

[00:25:26] Host Create clip One of our sky quirks is we're focusing on cellular processes the same way. There are a number of cellular processes associated with aging. As long as there was ever a period off time in our lifetimes where the body was able to reverse and restore the health at the cellular level, then we are pretty confident we can do it.

[00:25:50] Host Create clip Fantastic. Let me Old age only had take a quick poll and invite you to come to the microphone. How many of you feel you know, Bob and I wanted to bring these three colleagues up on stage to give you a sense of the different approaches towards longevity, right from blood factors from catching cancer in your degenerate disease and heart disease early so you could do something about it at stage zero. By the way, the comment I don't want to know what's going on inside my body is such bullshit, right? Of course, you want to know and you want to fix it right there at ST Zero just to be very clear about that, right? It's you making yourself the CEO of your own health and, of course, went signaling pathways. How many folks feel that after hearing this that you believe there might actually be an extra 20 healthy years in your life? Can you see a show of hands? So you and I and I believe that I think we're going to see in this next decade. Ah, an extension of the healthy human life span and vitality. Uh, this is gonna impact so many different factors in government and insurance in finance in all of these things. Right? So we have some questions, please.

[00:27:04] Host Create clip Thank you. Peter and ah, Bob for leading this revolution. So, Bob, have you ever looked that when you have these stem cells that you're injecting, how does it affect GDF 11 or Wnt signaling dis curious. If there's a connective ity and Amy, there are 50 different growth hormones, and I know GDF 11 is one, and that's what you discovered. So what are your thoughts on, like combining other, you know, hormones to amplify the effect. I know it's early stage and ah Osman I'm in Wnt is It's also very dangerous part. Wait, so tell us a little bit about the danger now, Roger, I love that because that really seemed like it was a setup question. Right? But, you know, let me just let me just say this, um, our approach, which is to take cells derived at the at the instant of birth. Ah, process store them and deliver them back in order to replace defective factors. Influence is everything that Amy and Osman have been speaking about. We don't as a matter of course, focus on specific, discreet factors because we believe that the delivery system we have in the whole cell is quite effective. However, that being said, all of the work that this whole panel is doing helps contribute to the underlying a mechanistic understanding that we need to justify it to regulators, to opinion leaders, to clinicians, scientists, et cetera. And so I'm gonna turn it over to Amy. But But the bottom line is, there's no doubt that these things play a role in cell therapy. It's just a different, a different way of delivering those factors.

[00:28:52] Host Create clip So So I'm gonna agree with Bob and say that this is a network that we're really looking into, and it can be perturbed and manipulated from many different points. We have looked actually to specifically answer your question about stem cells and GDF 11. We've made knock in my still I was to track producer cells of that particular protein, and we don't think stem cells are a major source of GDF 11. But that's likely because it's made in many different tissues and met. Many different cell types and stencils are rare within those tissues, so in terms of the amount of contribution those particular cells themselves would have it, it's low. But in that stem cells make the daughter cells that constitute the tissues that are the major producers. They're an important aspect of that regulation in terms of other growth factors. Obviously there Judith, 11 is one of ah very large family of growth factors. We know at least one of the um, other t JIA family members also acts in a positive manner for promoting rescue of re Meilin ating activity in the spinal cord. Ah, and so we think there may be some special place for this particular sub family in regulating regenerative responses with aging. But there's also it's also clear that non TGS members, non growth factor signals and also non protein signals are gonna be important. And ultimately, what we're hoping we'll build out is on understanding of all the key players, how they intersect with one another and predictive models for how a change in one would affect other key regulators that we could then have a better sense of how to intervene to set the system back to appropriate interaction.

[00:30:33] Host Create clip Osmond The dangers of manipulation went pathway

[00:30:36] Host Create clip so regarded in wind saved

[00:30:37] Host Create clip what could possibly go wrong.

[00:30:42] Host Create clip So wind has been around for the last 35 years. And you know, if you do apartment search today, you get more than 30,000 articles on the wind pathway so that the significance off the pathway is very well established. And because of that, since the early days, everybody has been trying to drug this pathway, come up with drugs. But so far, safety and efficacy have been mutually exclusive. You know, to your point about the safety of the wind pathway. What we have done differently is We actually identified a number off novel biological targets that people don't even know they belong in the wind pathway. And it turns out the just off the, ah reason why it is possible to do it safely and ification slee is because these targets are able to allow us to distinguish between healthy wind signaling and evident went signaling. So if you mess with healthy signaling, yes, you will always run into side effects, whereas with our targets we are able to, you know, if the signaling has turned aberrant, it corrects it. But if it is healthy, the drugs are enough. They have no impact on the signaling at that point, and proof is in the pudding. For example, you know our most advanced one is osteoarthritis. The cartel is growing drug to date between our face, one face to face to be and a number of long term monitoring trials.

[00:32:24] Host Create clip We have those two more than 1000 patients, and we have not observed a single drug related serious adversity, but not a single one.

[00:32:34] Host Create clip Amazing, Amazing Tika, let's take these three quick questions. We have five minutes left on the clock. Hello, This record from what I wanted to ask Dr Bob scenery. I don't have stem cells or present ourselves. He starts for me. Can you use any stem cells from the placenta in anybody? So So that's one of the elegant, uh, features of cells from the placenta. I think I mentioned the placenta is nature's professional Allah graph. Okay, the placenta is designed to, in essence, exist in a in a foreign body for nine months without inducing a rejection response. Okay, so if you think about this, a mother's contributes 50% of the D N A. To the developing fetus. She carries it for nine months. She doesn't reject it. It doesn't reject her. Well, Think about surrogate pregnancy. The mother's not even related to the fetus, and it carries it Without that rejection response. We've treated hundreds and hundreds and hundreds of patients with placental cells that were never matched to the recipient. We've never had any event of a graft rejection response that was a significant cause of any toxicity. So that means that placental cells are one size fits all. And so you were all in luck because, fortunately that that platform is available to treat anyone next question, please. Yeah. Howard Baru, common orthopedic surgeon from New Jersey. This is my second of three courses with this year. And I got to tell you what you do is just remarkable. Love it. Thank you. The question is, as an orthopedic surgeon or spying knees, this is really big economic challenge. How do you see this? Tying into maybe specialty clinics for orthopedics and spying and how we would be able to use that information into it.

[00:34:17] Host Create clip Uh, gentlemen, you wanna ask me to take it first and David little bit yourself?

[00:34:22] Host Create clip I'm so I didn't hear the question.

[00:34:23] Host Create clip How is how your treatment's gonna be used for in the orthopedics world looking and specialty clinics and so forth? What?

[00:34:30] Host Create clip Okay, so and, you know, going back to the progenitor of stem cells, Maison camo stem cells, everything to do with the muscular skeletal system. Right? So they know, For example, just because we call it a Masonic Amo stem cell does not make it identical cells across the body. The most bankable stem cells in the knee joint, for example, grow a certain type of cartilage. The maison camo stem cells in the spine grow a different type of cartilage, but the same went rest or it'd medicine. Let's say the same went in the same wind drug. The moment we triggered these molecules, their stamps else. I'm sorry. Back into a healthy range. They do whatever they know how to do, right? So the one in the spine grows a different type of cartilage that is suitable for a disc. Whereas there, the one for the joint. And we see this across all types of progenitor of stem cells. Right door most themselves. We put the same lotion on our scalp in gross hair, saying lotion. You put it over here. They've never grown here. They cannot. Instead, they differentiate into fibroblasts. They release collagen, fills up the nukes and crooks, and we eliminate the wrinkles so the stem cells know what their local is and what they're responsible for in that location.

[00:36:01] Host Create clip David Quick. So, you know, I would just add that, as you know, as I presented our whole body protocol, that's part of our precision health platform. We've really historically focused on five domains neurovascular noted genin of cardiovascular, metabolic and uncle logic. But a six domain that we're working on, I'm working actually with Seaman's on a whole body protocol for degenerative joint disease, really having precise measures of cartilage. And so the idea would be before you get sort of bone on bone. We want to be able to use cellular therapy to regrow that cartilage. But you have tohave precise ways right of measuring that cartilage pre and post. So you know, we again we've you kind of the minimally invasive cellular therapeutics as a natural partner of minimally invasive precision health analytics that can really give you diagnostics pre and post. So I think, in a way, that's how you know, sort of a cellular parity clinic batches with a person. You got one minute left last question, and I want to add just one thing, which is an orthopedic. Surgeons have been traditionally early adopters of psychotherapy routinely use these products. So the truth is, you're gonna wind up seeing use these technologies earlier than others.

[00:37:08] Host Create clip Okay, 1 28 is the new 80 if you can't in accidents. But my question is to ask Mom, if you have seen oh, ever tested any favorable effect with the ultrasound because it is known that ultrasound can actually heel bone fractures, wounds and so on.

[00:37:28] Host Create clip Are you asking about the safety of the efficacy? Efficacy? Okay, because regarding safety, we have looked at the joint with X Ray Emery Dex, I cat scan. And you know, it's all clean in terms of efficacy. Currently, the only clinically validated imaging modality I don't know

[00:37:46] Host Create clip about therapeutical to sell. No, not yes, yes.

[00:37:50] Host Create clip So the only clinically validated imaging that is accepted by the FDA is X ray. So we have looked at X ray in all three off the previous clinical trials and for the target patient population that we are going into our pivotal studies, we keep getting statistically significant and clinically significant. X ray results basically medial joint space with increase.

[00:38:16] Host Create clip I hope this session has uplifted your personal expectations of your healthy lifespan for that of your family. I think this is something that is the most exciting time ever to be alive. Please help Bob and I think our panel here get you guys